Doxorubicin nanoparticles - Onxeo

Drug Profile

Doxorubicin nanoparticles - Onxeo

Alternative Names: BA-003; Doxorubicin Transdrug; Doxorubicin-Transdrug; Livatag

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator BioAlliance Pharma
  • Developer CNRS; Onxeo SA
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Preclinical Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 10 May 2017 Onxeo receives patent allowance for Livatag® in USA
  • 21 Mar 2017 Pharmacodynamics data from a preclinical trial in Cancer released by Onxeo
  • 25 Jan 2017 Onxeo completes enrolment in its phase III trial for Hepatocellular carcinoma in USA, France, Spain, Belgium, Hungary, Austria, Italy, Egypt, Lebanon, Saudi Arabia, Turkey and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top